![]() |
RECTAS
- 英文名称:RECTAS
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11534
- cas:101862-47-9
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-04-30
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11534 |
用途 | 科研检测 |
英文名称 | RECTAS |
包装规格 | 1MG |
CAS编号 | 101862-47-9 |
别名 | RECTAS |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:>98% by TLC;NMR (Conforms)
分子式:C10H8ClN5O
分子量:249.66
溶剂:DMSO (27 mg/ml)
性状:Pale yellow solid
存储:-20°C
Activity (short version):pre-mRNA splicing modulator
Function / Pharmacology:RECTAS, a pre-mRNA splice modulator (Rectifier of Aberrant Splicing), was discovered in a small molecule screen for compounds that rectify aberrant IKBKAP splicing in cells from patients with familial dysautonomia. RECTAS (2 mM) increased the expression of IKAP and restored tRNA modifications.1,2 It directly interacts with CDC-like kinases enhancing SRSF6 phosphorylation.2 A combination treatment with RECTAS and phenylbutyric acid was shown to restore DJ-1 protein and mitochondrial dysfunction in Parkinson’s disease models.3
分子式:C10H8ClN5O
分子量:249.66
溶剂:DMSO (27 mg/ml)
性状:Pale yellow solid
存储:-20°C
Activity (short version):pre-mRNA splicing modulator
Function / Pharmacology:RECTAS, a pre-mRNA splice modulator (Rectifier of Aberrant Splicing), was discovered in a small molecule screen for compounds that rectify aberrant IKBKAP splicing in cells from patients with familial dysautonomia. RECTAS (2 mM) increased the expression of IKAP and restored tRNA modifications.1,2 It directly interacts with CDC-like kinases enhancing SRSF6 phosphorylation.2 A combination treatment with RECTAS and phenylbutyric acid was shown to restore DJ-1 protein and mitochondrial dysfunction in Parkinson’s disease models.3